RCS - Immupharma PLC - IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE

ImmuPharmaAnnouncement

08/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4505Sa&default-theme=true

RNS Number : 4505S  Immupharma PLC  08 January 2025

08 January 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA at JP MORGAN CONFERENCE and BIOTECH SHOWCASE

 11-16 JAN 2025, SAN FRANCISCO

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr
Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be
attending both the JP Morgan Conference and the Biotech Showcase from 11-16
January 2025, in San Francisco.

 

 

The JP Morgan conference and Biotech Showcase are annual premier partnering
events, designed to provide biotechnology companies with the opportunity to
present to and connect with global Biopharma companies and investors.

 

The advances made by ImmuPharma with the P140 program, particularly in the
latter part of 2024, have led to significant interest from leading
Biopharmaceutical companies and we are progressing  discussions as we move to
establish global licensing agreements.

 

There have been eleven $1bn+ licensing deals for immunology assets across the
BioPharma industry from 2023 to late September 2024. The current trend
suggests that Immunology and Autoimmune drug assets are becoming very highly
sought by the leading BioPharma companies.

 

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said:
"Attending and taking meetings at both the JP Morgan conference and the
Biotech Showcase offers the opportunity to continue discussions across our
whole unique portfolio and specifically with global BioPharma companies that
have an interest in autoimmune diseases demonstrated within our P140
technology platform. Our focus remains on track to establish global partnering
opportunities across all of our programs."

 

Ends

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             +44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140,is a first-in class "immune tolerance
restorer" for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases that share the
same mechanism of action.

 

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRMITMTMMBRA